• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study 
    •   QMRO Home
    • Blizard Institute
    • Centre for Immunobiology
    • Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study
    •   QMRO Home
    • Blizard Institute
    • Centre for Immunobiology
    • Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study

    Volume
    168
    Pagination
    124 - 134
    DOI
    10.1111/bjh.13112
    Journal
    BRITISH JOURNAL OF HAEMATOLOGY
    Issue
    1
    ISSN
    0007-1048
    Metadata
    Show full item record
    Authors
    Powell, JS; Apte, S; Chambost, H; Hermans, C; Jackson, S; Josephson, NC; Mahlangu, JN; Ozelo, MC; Peerlinck, K; Pasi, J
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/6728
    Collections
    • Centre for Immunobiology [1053]
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.